For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 0 |
| Research and development | 141,597 | 257,199 | 187,808 | 191,608 |
| General and administrative | 663,457 | 475,908 | 527,466 | 556,467 |
| Total operating expenses | 805,054 | 733,107 | 715,274 | 748,075 |
| Loss from operations | -805,054 | -733,107 | -715,274 | -748,075 |
| Change in fair value of warrant liability | -265 | -498 | -1,212 | -902 |
| Interest income | 38,801 | 47,966 | 47,325 | 6,654 |
| Total other income | 39,066 | 48,464 | 48,537 | 7,556 |
| Net loss | -765,988 | -684,643 | -666,737 | -740,519 |
| Net loss attributable to common stockholders | - | -684,643 | -666,737 | - |
| Basic EPS | -0.43 | -0.583 | -0.37 | -1.33 |
| Diluted EPS | -0.43 | -0.583 | -0.37 | -1.33 |
| Basic Average Shares | 1,795,260 | 1,174,869* | 1,795,097 | 557,787 |
| Diluted Average Shares | 1,795,260 | 1,174,869* | 1,795,097 | 557,787 |
Bone Biologics Corp (BBLG)
Bone Biologics Corp (BBLG)